Send to

Choose Destination
Future Med Chem. 2019 Apr;11(8):847-855. doi: 10.4155/fmc-2018-0313. Epub 2019 Apr 17.

Design and implementation of novel nutraceuticals and derivatives for treating intestinal disorders.

Author information

Department of Surgery, Yale University School of Medicine, New Haven, CT 06520, USA.
Department of Cellular & Molecular Physiology, Yale University School of Medicine, New Haven, CT 06520, USA.


Gastrointestinal illnesses pose a significant worldwide disease burden and are associated with an array of medicinal and surgical therapies. Standard pharmaceutical options have adverse effects, prompting the rise of nutraceutical or food-derivative therapies. Here, we present an overview of the current nutraceutical therapies in gastrointestinal disease. We then introduce the calcium-sensing receptor (CaSR) as a novel therapeutic target. A G-protein-coupled receptor found in apical and basal intestinal cells, the CaSR modulates intestinal fluid secretion and mucosal integrity. Applying nutraceuticals that upregulate the CaSR may alleviate symptoms seen across a spectrum of illnesses. At last, we discuss how nanoparticle technology can be implemented to effectively deliver nutraceuticals to diseased regions of the intestine, thereby minimizing systemic side effects.


calcium-sensing receptor; gastrointestinal disorders; inflammation; nanoparticles; nutraceutical; pharmaceutical


Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center